Sector News

Mallinckrodt buys Ikaria for $2.3bn

March 6, 2015
Life sciences
Dublin, Ireland-based speciality biopharma Mallinckrodt is extending its hospital-based offering with a $2.3-billion purchase of US privately-held critical care group Ikaria.
 
A Mallinckrodt subsidiary will acquire the company from a Madison Dearborn-led investor group, with the transaction is expected to close early in the second quarter assuming closing conditions are satisfied.
 
The firm says the deal will further accelerate growth in its Specialty Brands segment, broaden its hospital presence, and diversify its portfolio with “high-value, high-margin critical care products”.
 
The move is expected to add at least $150 million in net sales and be accretive to Mallinckrodt’s fiscal year 2015 adjusted diluted earnings per share by at least $0.25 per share.
 
By Selina McKee
 
Source: Pharma Times

comments closed

Related News

April 26, 2024

Former Bristol Myers CEO tapped as Novartis’ next board chair

Life sciences

Giovanni Caforio, the former CEO of Bristol Myers Squibb, is set to become the next board chairman of Novartis, which on Tuesday proposed the pharmaceutical industry veteran as its pick to replace Joerg Reinhardt in the role next year. Reinhardt has served as Novartis’ chair since 2013 and plans to retire when his 12-year term ends in 2025.

April 26, 2024

GE HealthCare launches voice-activated, AI-powered ultrasound machines for women’s health

Life sciences

GE HealthCare has raised the curtain on two ultrasound systems equipped with artificial intelligence programs designed to assist in diagnosing conditions in women’s health, including obstetric exams. The Voluson Signature 20 and 18 imaging systems include AI tools capable of automatically identifying and annotating measurements of fetal anatomy.

April 26, 2024

Scientists reveal new method that could reduce waste from drug manufacturing

Life sciences

Scientists from the University of Edinburgh’s School of Chemistry have revealed a new sustainable method of manufacturing complex molecules that could reduce waste produced during drug production. The method published in Nature Chemistry could help to prevent severe side effects caused by drugs that can exist as enantiomers.

How can we help you?

We're easy to reach